Harry Sequeira Gross
Hematology & Oncology · Baton Rouge, LANPI 1841851391
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,987 of the $4,212 with a category attached, or 70.9%. 28 manufacturers reported payments, led by Adaptive Biotechnologies Corporation at 37.2% of the total. 2025 is the largest year on record at $3,216, more than ten times the $287 reported in 2023. That places this record below the midpoint for hematology & oncology clinicians in LA, where the typical reported total is $4,451.
Across 76 payments — averaging $55.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Adaptive Biotechnologies Corporation$2K
- Incyte Corporation$301
- Gilead$267
- Springworks Therapeutics, Inc.$253
- Lilly USA, LLC$172
- Genentech USA, Inc.$163
- plus $1K from 22 others
Across 1 payment — averaging $53,312 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$53K
What the payments were for
- Travel & lodging$96023%
- Food & beverage$2,98771%
- Education$2656%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Adaptive Biotechnologies Corporation | 15 | $1,566 |
| Incyte Corporation | 5 | $301 |
| Gilead(2 entities) | 5 | $267 |
| Springworks Therapeutics, Inc. | 4 | $253 |
| Lilly USA, LLC | 7 | $172 |
| Genentech USA, Inc. | 6 | $163 |
| Janssen Research & Development, LLC | 1 | $146 |
| Beigene USA, Inc. | 1 | $145 |
| Syndax Pharmaceuticals, Inc. | 1 | $130 |
| Medexus Pharma, Inc. | 1 | $127 |
| Beone Medicines USA, Inc. | 1 | $104 |
| Astellas Pharma US Inc | 1 | $99 |
| Daiichi Sankyo Inc. | 4 | $97 |
| Bayer | 4 | $95 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $95 |
| Pfizer | 2 | $61 |
| Sobi, Inc | 2 | $55 |
| Johnson & Johnson | 3 | $51 |
| AstraZeneca | 2 | $48 |
| Jazz Pharmaceuticals Inc. | 1 | $36 |
| Amgen | 1 | $31 |
| Servier Pharmaceuticals LLC | 1 | $27 |
| Sanofi-aventis U.S. LLC | 1 | $26 |
| Pharmaessentia USA Corporation | 1 | $26 |
| Merck | 1 | $26 |
| Mirati Therapeutics, Inc. | 1 | $25 |
| GSK | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,212 in reported general payments places this provider in the 45th percentile of 183 hematology & oncology providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GavretoPralsetinib | 12 | $68,165 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Baton Rouge
- Hana SafahBaton Rouge$2M
- Nakhle SabaBaton Rouge$842K
- Sanjay JunejaBaton Rouge$346K
- Andrew DalovisioBaton Rouge$128K
- Greg BizetteBaton Rouge$32K
- Marshall StaggBaton Rouge$19K
- Christopher McCanlessBaton Rouge$18K
- Georgios ConstantinouBaton Rouge$15K
- Lauren JunejaBaton Rouge$14K
- Victor LinBaton Rouge$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.